These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22350899)

  • 1. Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.
    Gallastegui N; Groll M
    Methods Mol Biol; 2012; 832():373-90. PubMed ID: 22350899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and development of second-generation proteasome inhibitors.
    Kirk CJ
    Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development and clinical application of novel proteasome inhibitors].
    Iida S
    Rinsho Ketsueki; 2012 Apr; 53(4):417-25. PubMed ID: 22687975
    [No Abstract]   [Full Text] [Related]  

  • 5. Second Generation Proteasome Inhibitors in Multiple Myeloma.
    Gozzetti A; Papini G; Candi V; Brambilla CZ; Sirianni S; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(7):920-926. PubMed ID: 27592543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification, crystallization, and X-ray analysis of the yeast 20S proteasome.
    Groll M; Huber R
    Methods Enzymol; 2005; 398():329-36. PubMed ID: 16275340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
    Chauhan D; Catley L; Li G; Podar K; Hideshima T; Velankar M; Mitsiades C; Mitsiades N; Yasui H; Letai A; Ovaa H; Berkers C; Nicholson B; Chao TH; Neuteboom ST; Richardson P; Palladino MA; Anderson KC
    Cancer Cell; 2005 Nov; 8(5):407-19. PubMed ID: 16286248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.
    Gräwert MA; Groll M
    Chem Commun (Camb); 2012 Feb; 48(10):1364-78. PubMed ID: 22039589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
    Huber EM; Groll M
    Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914.
    Huber EM; Heinemeyer W; Groll M
    Structure; 2015 Feb; 23(2):407-17. PubMed ID: 25599643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Proteasome inhibitors in cancer therapy].
    Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
    Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
    Schrader J; Henneberg F; Mata RA; Tittmann K; Schneider TR; Stark H; Bourenkov G; Chari A
    Science; 2016 Aug; 353(6299):594-8. PubMed ID: 27493187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)-Homosalinosporamide A and Its Mode of Proteasome Inhibition: An X-ray Crystallographic Study.
    Groll M; Nguyen H; Vellalath S; Romo D
    Mar Drugs; 2018 Jul; 16(7):. PubMed ID: 30029468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innovation in myeloma treatments PARP excellence!
    Fonseca R
    Blood; 2011 Dec; 118(24):6234-5. PubMed ID: 22161848
    [No Abstract]   [Full Text] [Related]  

  • 16. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
    Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
    Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Balsas P; Galán-Malo P; Marzo I; Naval J
    Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
    Landis-Piwowar KR; Milacic V; Chen D; Yang H; Zhao Y; Chan TH; Yan B; Dou QP
    Drug Resist Updat; 2006 Dec; 9(6):263-73. PubMed ID: 17197231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A.
    Kale AJ; McGlinchey RP; Lechner A; Moore BS
    ACS Chem Biol; 2011 Nov; 6(11):1257-64. PubMed ID: 21882868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition.
    Groll M; McArthur KA; Macherla VR; Manam RR; Potts BC
    J Med Chem; 2009 Sep; 52(17):5420-8. PubMed ID: 19678642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.